Medimmune Limited

Ross Anthony Stewart

Michelle Morrow

Ian Nevin Foltz

Jaspal Singh Kang

Scott A Hammond

Melanie Boyle

Matthieu Chodorge

Laura Sekirov

Marat Alimzhanov

Kathleen Ann Mulgrew

Christophe Queva

John Babcock

John Stephen Babcook

Andrew Grier Buchanan

Nicholas Durham

Simon Dovedi

Daniel Ramsay Higazi

Edmund Poon

Sudharsan Sridharan

Robert Wilkinson

Tim Illidge

Natalie Jo Tigue

Mathieu Chodorge

Lesley Lynn Young

Lisa Bamber

Rebecca Leyland

Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.

Targeted binding agents against B7-H1

The disclosure provides GITRL fusion polypeptide subunits comprising an IgG Fc domain, a trimerization domain, and the receptor binding domain of GITR ligand, where the fusion polypeptide subunits can self-assemble into hexameric proteins. Also provided are methods of making fusion polypeptide subunits and hexameric proteins, and methods of use, e.g., treatment of cancer.

GITRL fusion proteins comprising a human coronin 1a derived trimerization domain

This application provides a method of treating cancer in a patient comprising administering at least one dose of radiation therapy and at least one PD-1 and/or PD-L1 antagonist, wherein at least one PD-1 and/or PD-L1 antagonist is administered on the same day as a dose of radiation therapy or up to and including 4 days later.

Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy

The present invention provides antibodies and antigen-binding fragments that specifically bind PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer and other immune system disorders.

Antibodies against PD-1 and uses thereof

Growing community of inventors

Cambridge, United Kingdom

Ross Anthony Stewart